Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes

Cheran Elangovan, Adeolu Morawo, Aiesha Ahmed

Research output: Contribution to journalReview article

Abstract

Purpose of review: Peripheral nerve hyperexcitability (PNH) syndromes are divided into primary and secondary groups based on the presence or absence of demonstrable peripheral nerve disease. In this review, we systematically evaluate the evidence for current therapies and supportive managements based on autoimmune, paraneoplastic, and genetic components in pathophysiology reported in the literature. Recent findings: Current therapy options are based on symptomatic management as well as focusing the underlying immune/genetic/paraneoplastic pathology by immunosuppressants, chemotherapy, and surgery. Summary: Further research is desired to provide treatment options geared specifically towards addressing PNH. Supportive care can also be an area for future research.

Original languageEnglish (US)
Article number23
JournalCurrent Treatment Options in Neurology
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Peripheral Nerves
Peripheral Nervous System Diseases
Immunosuppressive Agents
Therapeutics
Pathology
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

@article{f9ccdcf4a36141ecb925c488c062bd3d,
title = "Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes",
abstract = "Purpose of review: Peripheral nerve hyperexcitability (PNH) syndromes are divided into primary and secondary groups based on the presence or absence of demonstrable peripheral nerve disease. In this review, we systematically evaluate the evidence for current therapies and supportive managements based on autoimmune, paraneoplastic, and genetic components in pathophysiology reported in the literature. Recent findings: Current therapy options are based on symptomatic management as well as focusing the underlying immune/genetic/paraneoplastic pathology by immunosuppressants, chemotherapy, and surgery. Summary: Further research is desired to provide treatment options geared specifically towards addressing PNH. Supportive care can also be an area for future research.",
author = "Cheran Elangovan and Adeolu Morawo and Aiesha Ahmed",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s11940-018-0510-9",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "7",

}

Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes. / Elangovan, Cheran; Morawo, Adeolu; Ahmed, Aiesha.

In: Current Treatment Options in Neurology, Vol. 20, No. 7, 23, 01.07.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current Treatment Options for Peripheral Nerve Hyperexcitability Syndromes

AU - Elangovan, Cheran

AU - Morawo, Adeolu

AU - Ahmed, Aiesha

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose of review: Peripheral nerve hyperexcitability (PNH) syndromes are divided into primary and secondary groups based on the presence or absence of demonstrable peripheral nerve disease. In this review, we systematically evaluate the evidence for current therapies and supportive managements based on autoimmune, paraneoplastic, and genetic components in pathophysiology reported in the literature. Recent findings: Current therapy options are based on symptomatic management as well as focusing the underlying immune/genetic/paraneoplastic pathology by immunosuppressants, chemotherapy, and surgery. Summary: Further research is desired to provide treatment options geared specifically towards addressing PNH. Supportive care can also be an area for future research.

AB - Purpose of review: Peripheral nerve hyperexcitability (PNH) syndromes are divided into primary and secondary groups based on the presence or absence of demonstrable peripheral nerve disease. In this review, we systematically evaluate the evidence for current therapies and supportive managements based on autoimmune, paraneoplastic, and genetic components in pathophysiology reported in the literature. Recent findings: Current therapy options are based on symptomatic management as well as focusing the underlying immune/genetic/paraneoplastic pathology by immunosuppressants, chemotherapy, and surgery. Summary: Further research is desired to provide treatment options geared specifically towards addressing PNH. Supportive care can also be an area for future research.

UR - http://www.scopus.com/inward/record.url?scp=85047878200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047878200&partnerID=8YFLogxK

U2 - 10.1007/s11940-018-0510-9

DO - 10.1007/s11940-018-0510-9

M3 - Review article

VL - 20

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 7

M1 - 23

ER -